Fulvestrant for breast cancer (2002)
Fulvestrant was approved in 2002 for breast cancer that had progressed after tamoxifen. It degrades the estrogen receptor instead of only blocking it.
It gave patients with hormone-resistant breast cancer another endocrine option.
Receptor degradation became a proven strategy in breast cancer, separate from receptor blockade.
Bavdegalutamide applies the same logic to the androgen receptor in prostate cancer.
